<unk>  is a sodium-glucose cotransporter 2 (SGLT-2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor combination product that is FDA approved for the improved glycemic control of adults with type 2 diabetes mellitus (T2DM) who have inadequate control with<unk>  or who are already treated with<unk>  and saxagliptin.   Common adverse reactions include upper respiratory tract infection, urinary tract infection, and dyslipidemia.
Dapagliflozin / saxagliptin
Pioglitazone And Metformin hydrochloride
Pioglitazone/Glimepiride
Linagliptin and Metformin hydrochloride
Saxagliptin hydrochloride and Metformin hydrochloride
Sitagliptin And Metformin Hydrochloride
Repaglinide and Metformin hydrochloride
Glyburide and Metformin hydrochloride